At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed adenocarcinoma of pancreas not amenable to curative surgery (locally advanced, metastatic, or recurrent)
- ✓Karnofsky Performance Status ≥60
- ✓Measurable disease
- ✓Age ≥18 years
- ✕History of treated or active brain metastases, carcinomatous meningitis, uncontrolled seizure disorder, or active neurological disease
- ✕Unstable medical condition including uncontrolled diabetes, hypertension, active infections, unstable CHF, uncontrolled arrhythmias, or coagulation disorders
- ✕Pregnant or breast feeding
- ✕Investigational agent within 4 weeks of study entry
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Curcumin for Pancreatic Neoplasms and Adenocarcinoma. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if treatment with curcumin can help shrink or slow the growth of pancreatic cancers. The effect of curcumin on the way pancreatic cancer cells function and the safety of treatment with curcumin will also be studied.
Study Details
Timeline
Interventions
Starting dose 8 gm orally per day for 8 weeks. If patient experiences grade III toxicity, dose held and restarted with a 50% dose reduction after resolution of toxicity to \</= Grade I. Patients with grade IV toxicity will discontinue treatments. Patients with \</= grade I toxicity may have a 25% dose increase at each four-week period. Patients will continue on treatment until disease progresses, unless Grade III toxicity supervenes.